# Forbion Capital Partners

> Forbion Capital Partners is a VC fund backing Biotechnology and Health Care. See 209 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Naarden, The Netherlands
- Total investments: 209
- Last investment: Aug 2026
- Lead investor: 53%
- Last fund: Oct 2024
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/forbion-capital-partners
- X (Twitter): https://twitter.com/forbionlifesci 
- Website: http://www.forbion.com

Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successfulinvestments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.

## Contacts

5 contacts available for Forbion Capital Partners. Shizune tracks 20 team members at Forbion Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/forbion-capital-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $19M–$180M |
| Series B | $16M–$155M |
| Series C | $19M–$120M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 90 | 43% |
| Health Care | 50 | 24% |
| Medical | 45 | 22% |
| Therapeutics | 39 | 19% |
| Pharmaceutical | 28 | 13% |

27 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 43 | 21% |
| Series A | 39 | 19% |
| Series C | 20 | 10% |
| Series D | 15 | 7% |
| Seed | 9 | 4% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 35 | 17% |
| United Kingdom | 21 | 10% |
| The Netherlands | 11 | 5% |
| Germany | 9 | 4% |
| Switzerland | 6 | 3% |

16 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Joy Faucher | General Partner | 4 | https://shizune.co/investors/profile/joy-faucher-c13e |
| Marco Boorsma | General Partner | 13 | https://shizune.co/investors/profile/marco-boorsma |
| Nanna Lüneborg | General Partner | 14 | https://shizune.co/investors/profile/nanna-lneborg |
| Onno Stolpe | Venture Partner | 1 | https://shizune.co/investors/profile/onno-van-de-stolpe |
| Sander Slootweg | Managing Partner and co-founder | 7 | https://shizune.co/investors/profile/sander-slootweg |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Expedition Therapeutics | Expedition Therapeutics operates as an unincorporated association. | $115M | Series B | Aug 05, 2026 |  |
| RQ Bio | RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-risk subjects. The company's mission is to deliver "instant immunity" through passiveimmunization, helping protect vulnerable populations such as the elderly, newborns, and immunocompromised patients from severe infectious diseases. The company specializes in the discovery and development of broad-spectrum antiviral antibodies that are engineered to remain effective even as viruses evolve. Its scientific approach combines virology, antibody engineering, computational biology, and immune-directed discovery techniques to identify potent antibodies that target conserved regions of viral proteins, reducing the risk of resistance caused by viral mutations.RQ Bio's lead programs focus on infectious diseases such as influenza, COVID-19, respiratory syncytial virus (RSV), and cytomegalovirus (CMV). The company is currently developing long-acting monoclonal antibodies designed to provide once-yearly protection against seasonal influenza, particularly for individuals at high risk of severe disease. | $112.5M | Series A | Jun 24, 2026 |  |
| Memento Medicines | Memento Medicines is a biotechnology company focused on the development of novel antibody therapies for ophthalmology. The company's core business model centers on licensing and advancing specialized, multi-target biologics to address high-demand clinical needs in the retinal disease landscape. Its primary value proposition rests on its leadprogram, MMT-205, a dual-action bispecific antibody engineered to simultaneously activate Tie2 receptors and inhibit VEGF. This therapeutic candidate is being clinical developed to improve treatment durability and visual outcomes for individuals suffering from neovascular age-related macular degeneration and diabetic macular edema. | $93M | Series A | Jun 18, 2026 |  |
| cAMPfield Therapeutics | cAMPfield Therapeutics is a biotechnology company that specializes on exploration and development activities of therapeutic solutions. | $180M | Series A | May 20, 2026 |  |
| CellCentric | CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $220M | Series D | May 06, 2026 |  |
| Coultreon Biopharma | Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. | $125M | Series A | Apr 28, 2026 |  |
| Mestag Therapeutics | Mestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology. | $40M | Venture - Series Unknown | Mar 17, 2026 |  |
| Tropic Biosciences | At Tropic Biosciences, They develop high-performing commercial varieties of tropical crops which promote grower wellbeing, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques. | $105M | Series C | Mar 12, 2026 |  |
| Slate Medicines | Slate Medicines is a biotechnology company that develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention. The company aims to revolutionize migraine prevention for patients seeking alternative solutions. | $130M | Series A | Feb 24, 2026 |  |
| Altesa | Altesa is a clinical-stage biopharmaceutical company dedicated to accelerating the development of new treatments against age-old threats to human health: high-consequence viral pathogens. | $75M | Series B | Feb 19, 2026 |  |

10 of 209 investments shown.

## Co-investors
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 28 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 24 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 23 deals together
- [Syncona Partners LLP](https://shizune.co/investors/profile/syncona-partners-llp) — VC Fund, 17 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 16 deals together
- [Ysios Capital](https://shizune.co/investors/profile/ysios-capital) — VC Fund, 15 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Medical VC Funds](https://shizune.co/investors/medical-vc-funds)
- [Medical Investors](https://shizune.co/investors/medical-investors)

## FAQ

### What does Forbion Capital Partners invest in?

Forbion Capital Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 209 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Forbion Capital Partners's check size?

Forbion Capital Partners typically joins rounds of $19M–$180M at Series A, $16M–$155M at Series B and $19M–$120M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Forbion Capital Partners participates in.

### How do I contact Forbion Capital Partners?

Public channels for Forbion Capital Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Forbion Capital Partners?

The team at Forbion Capital Partners includes Joy Faucher (General Partner), Marco Boorsma (General Partner) and Nanna Lüneborg (General Partner), among 20 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co